Abbott Kaletra
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Combination protease inhibitor lopinavir/ritonavir received accelerated approval from FDA Sept. 15, two and a half months after its NDA was submitted. Abbott expects to submit data for full approval within two years. The submission will contain final study reports on a head-to-head study with Pfizer/Agouron's Viracept (nelfinavir) and data from an open trial of Kaletra vs. investigator-selected PIs in combination with Roxane's Viramune (nevirapine) and two nucleoside reverse transcriptase inhibitors in previously treated patients. Kaletra is indicated for use "in combination with other antiretroviral agents for the treatment of HIV infection" in patients six months and older and is dosed twice daily. Abbott is conducting a 35-patient study of once-daily Kaletra administratio
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.